276 related articles for article (PubMed ID: 14586413)
1. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.
Horiguchi K; Tomizawa Y; Tosaka M; Ishiuchi S; Kurihara H; Mori M; Saito N
Oncogene; 2003 Oct; 22(49):7862-5. PubMed ID: 14586413
[TBL] [Abstract][Full Text] [Related]
2. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas.
Hesson L; Bièche I; Krex D; Criniere E; Hoang-Xuan K; Maher ER; Latif F
Oncogene; 2004 Mar; 23(13):2408-19. PubMed ID: 14743209
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
Dammann R; Yang G; Pfeifer GP
Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
[TBL] [Abstract][Full Text] [Related]
4. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development.
Lusher ME; Lindsey JC; Latif F; Pearson AD; Ellison DW; Clifford SC
Cancer Res; 2002 Oct; 62(20):5906-11. PubMed ID: 12384556
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
6. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
7. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
8. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
10. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
Liu L; Yoon JH; Dammann R; Pfeifer GP
Oncogene; 2002 Oct; 21(44):6835-40. PubMed ID: 12360410
[TBL] [Abstract][Full Text] [Related]
11. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of the RASSF1A gene in gliomas.
Gao Y; Guan M; Su B; Liu W; Xu M; Lu Y
Clin Chim Acta; 2004 Nov; 349(1-2):173-9. PubMed ID: 15469871
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
14. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
15. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
Qiu GH; Tan LK; Loh KS; Lim CY; Srivastava G; Tsai ST; Tsao SW; Tao Q
Oncogene; 2004 Jun; 23(27):4793-806. PubMed ID: 15122337
[TBL] [Abstract][Full Text] [Related]
16. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
Lo KW; Kwong J; Hui AB; Chan SY; To KF; Chan AS; Chow LS; Teo PM; Johnson PJ; Huang DP
Cancer Res; 2001 May; 61(10):3877-81. PubMed ID: 11358799
[TBL] [Abstract][Full Text] [Related]
17. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
[TBL] [Abstract][Full Text] [Related]
18. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas.
Dammann R; Takahashi T; Pfeifer GP
Oncogene; 2001 Jun; 20(27):3563-7. PubMed ID: 11429703
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic inactivation of RASSF1A in head and neck cancer.
Dong SM; Sun DI; Benoit NE; Kuzmin I; Lerman MI; Sidransky D
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3635-40. PubMed ID: 14506151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
